An interventional study of questionnaire administration and quality-of-life assessment in Hematopoietic/Lymphoid Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by City of Hope Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Hematologic Neoplasms by City of Hope Medical Center — 2 open to participants now, 13 under way, 1 of them phase 3. Hematologic Neoplasms · City of Hope Medical Center.
Among the 25 studies in Hematologic Neoplasms by City of Hope Medical Center, this one is the 2nd largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2013, is one of 8 with no phase, and was the 2nd registered.
1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.
Browse Hematologic Neoplasms studies →2 of the 25 studies in Hematologic Neoplasms by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+ · Healthy volunteers
City of Hope Medical Center
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 1
First in 2011; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 211 is above the median of 46 across 1,047 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 20 across the 19 interventional studies, 127 across the 6 observational. Of the 7 that completed or were terminated, 2 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
6 of the studies in Hematologic Neoplasms by City of Hope Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05173961City of Hope Medical CenterA Mobile Application, Oncpatient, to Assist Patients Undergoing Radiation Therapy | 2027-01-01 |
| NCT02041416City of Hope Medical CenterTechnology to Assess Vulnerable Older Adults With Cancer and Their Caregivers | 2027-01-06 |
| NCT04914338City of Hope Medical CenterA Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation | 2027-02-02 |
| NCT03922035City of Hope Medical CenterCBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant | 2027-02-05 |
| NCT04537871City of Hope Medical CenterCardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study | 2027-05-25 |
Add all 6 to your calendar (.ics) → With an account.
Among the 25 studies in Hematologic Neoplasms by City of Hope Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial studies quality of life in caregivers of hospitalized older patients with cancer.
PRIMARY OBJECTIVES:
I. Identify patient and caregiver factors associated with increased caregiver burden and decreased quality of life in caregivers of older adults with cancer.
SECONDARY OBJECTIVES:
I. Determine characteristics of informal caregivers of older adults with cancer admitted to hospital.
II. Determine type and amount of care informal caregivers provide for older adults with cancer admitted to hospital.
III. Determine quality of life in informal caregivers of older adults with cancer admitted to hospital.
IV. Identify caregiver needs, both informational and resource related. V. Explore the association between re-admission to the hospital within 30 days and caregiver burden.
VI. Explore whether feedback of information attained from the assessment of the caregiver influences services implemented by the health care team.
VII. Determine reasons for non-participation.
OUTLINE:
Caregivers complete a questionnaire about their sociodemographics, physical health, social supports, social activity, mental health and caregiver burden. They will also provide an assessment of the person they care for.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Caregivers complete a self-administered questionnaire about factors associated with increased caregiver burden and decreased quality of life.
Other: questionnaire administration · Procedure: quality-of-life assessment
Ancillary studies
Ancillary studies
Also known as: quality of life assessment
Caregiver burden and caregiver quality of life as measured by the Caregiver Quality of Life-Cancer Index
Univariate analyses will be performed to test differences in the Caregiver Quality of Life-Cancer Index (CQOLC) total score and score of each domain (burden, distinctiveness, positive adaption, and financial concern) across categorical variables (analysis of variance \[ANOVA\]), and simple linear regression will be used to test association of CQOLC total score with continuous and categorical variables.
Time frame: Up to 1 year
Ran from Jul 2013 to primary completion in May 2014, 10 months.
Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's 10 months is below that.
Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.
Start moved once since we started tracking on Sep 25, 2026: Jun 2013 → Jul 2013, on Oct 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.